GL1X · GenesisL1 explorer

MolNFT v1 · #123951 · protein

Human factor xa in complex with synthetic inhibitor benzylsulfonyl- DSER(BENZYL)-gly-4-amidinobenzylamide

5K0H · Coagulation factor X: “Human factor xa in complex with synthetic inhibitor benzylsulfonyl- DSER(BENZYL)-gly-4-amidinobenzylamide”. X-ray diffraction, 2 ligands (6PK, CA), 3 pockets (best druggability 0.46). MolNFT v1 #123951 on…

PDB
5K0H
Type
protein
Length
285 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Coagulation factor X
EC
3.4.21.6
UniProt
P00742
Ligands
6PK, CA
Pockets
3 · best druggability 0.46

Structure

x-ray diffraction · 2 distinct chains · 12% helix, 35% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACoagulation factor X (EC 3.4.21.6)protein23413% helix, 36% strandP00742
BCoagulation factor X (EC 3.4.21.6)protein518% helix, 31% strandP00742

Ligands and binding sites

  • 6PK · O-benzyl-N-(benzylsulfonyl)-D-seryl-N-[(4-carbamimidoylphenyl)methyl]glycinamide · ligand · chains A
  • CA · Calcium ion · metal · 2 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11450.460.7626empty
21050.440.78256PK
3510.280.7512empty

Interfaces

1 interface between chains.

  • A–B · 899 Ų buried · 10 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 8 disulfide (disulfide).

Compared structures

  • 5K0H · Human factor Xa in complex with synthetic inhibitor… · the same entry in another collection · chain A against A, TM-score 1.00
  • P00742 · AlphaFold monomer V2.0 prediction for coagulation factor X (P00742) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.